Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Windtree’s Phase II Success In Cardiogenic Shock Could Lead To Heart Failure Opportunity

Executive Summary

On the way to seeking approval for istaroxime in acute heart failure, Windtree became convinced that early cardiogenic shock could be a good get-to-market strategy for its blood pressure-improving drug.

You may also be interested in...



La Jolla’s Giapreza: Emergency Use Requests Sped US FDA Approval For Septic Shock

After publication of ATHOS-3 study results, agency received several requests from medical community for emergency use in hospitalized patients with shock and hypotension unresponsive to available therapy, spurring FDA to take an approval action two months ahead of user fee goal date.

Cidara’s Novel Antifungal Approved For Antimicrobial-Resistant C. Auris Infections

Cidara’s US commercial partner Melinta will launch the novel echinocandin this summer, announcing pricing shortly before rollout. Limited indication follows recommendation of FDA advisory panel.

89bio’s Phase IIb Data Heighten Competition Within NASH FGF21 Analog Class

89bio’s pegozafermin met co-primary endpoints of fibrosis reduction and NASH resolution in Phase IIb; the company said its methodology yielded lower placebo responses than in Akero’s Phase IIb study.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel